Beroctocog alfa
- Generic Name
- Beroctocog alfa
- Brand Names
- Alphanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9001-27-8
- Unique Ingredient Identifier
- 17RNR4H479
- Indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated. It is not indicated for patients with...
- Associated Conditions
- Bleeding
- Associated Therapies
- Perioperative management therapy
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 361
- Registration Number
- NCT02976753
- Locations
- 🇮🇹
Swedish Orphan Biovitrum Research Site, Padova, Italy
🇬🇧Swedish Orphan Biovitrum Reserach site, London, United Kingdom
🇪🇸Swedish Orphan Biovitrum research site, Alicante, Spain
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01561391
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath